PepGen (PEPG) Non Operating Income (2021 - 2026)
PepGen (PEPG) posted Non Operating Income of $1.2 million for Q1 2026, down 15.56% sequentially from $1.4 million in Q4 2025, and up 6.7% YoY from $1.1 million in Q1 2025.
PepGen (PEPG) Non Operating Income (2021 - 2026) Analysis & Trends
PepGen has reported Non Operating Income for 6 years, with the latest figure at $1.2 million in Q1 2026.
- Quarterly Non Operating Income rose 6.7% year-over-year to $1.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.1 million (down 37.04% YoY) and the FY2025 annual result came in at $4.0 million, down 43.9% from the prior year.
- Non Operating Income retreated to $1.2 million in Q1 2026 per PEPG's latest filing, from $1.4 million in the prior quarter.
- Over five years, Non Operating Income peaked at $2.1 million in Q2 2024 and troughed at $67000.0 in Q1 2022.
- A 5-year average of $1.3 million and a median of $1.4 million in 2025 frame the typical range for Non Operating Income.
- The sharpest annual moves came in 2022 and 2025: Non Operating Income soared 2885.29% in 2022, then tumbled 64.86% in 2025.
- Over 5 years, Non Operating Income stood at $1.6 million in 2022, then decreased by 11.13% to $1.4 million in 2023, then increased by 6.98% to $1.5 million in 2024, then retreated by 4.85% to $1.4 million in 2025, then fell by 15.56% to $1.2 million in 2026.
- According to Business Quant data, Non Operating Income over the past three periods registered $1.2 million, $1.4 million, and $628000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -139.24 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 12.40 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -51.63 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -53.64 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | PepGen | 207.09 Mn | 207.09 Mn | - | 1.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.14 Mn |
| Mar 31, 2026 | 1.19 Mn |
| Dec 31, 2025 | 1.41 Mn |
| Sep 30, 2025 | 628,000.00 |
| Jun 30, 2025 | 845,000.00 |
| Mar 31, 2025 | 1.12 Mn |
| Dec 31, 2024 | 1.49 Mn |
| Sep 30, 2024 | 1.79 Mn |
| Jun 30, 2024 | 2.09 Mn |
| Mar 31, 2024 | 1.78 Mn |
| Dec 31, 2023 | 1.39 Mn |
| Sep 30, 2023 | 1.49 Mn |
| Jun 30, 2023 | 1.62 Mn |
| Mar 31, 2023 | 1.71 Mn |
| Dec 31, 2022 | 1.56 Mn |
| Sep 30, 2022 | 947,000.00 |
| Jun 30, 2022 | 326,000.00 |
| Mar 31, 2022 | 67,000.00 |
| Dec 31, 2021 | 67,000.00 |
| Sep 30, 2021 | -34,000.00 |